Volume 14, Number 6—June 2008
Dispatch
Ceftriaxone-Resistant Salmonella enterica Serotype Newport, France
Table
Drug | % Resistant isolates |
|||||
---|---|---|---|---|---|---|
2000 (n = 100) (N = 109) | 2001 (n = 124) (N = 134) | 2002 (n = 66) (N = 71) | 2003 (n = 126) (N = 138) | 2004 (n = 91) (N = 94) | 2005 (n = 78) (N = 80) | |
Amoxicillin | 27 | 9.7 | 1.5 | 19.8 | 8.8 | 3.8 |
Ceftriaxone/ceftazidime | 15 | 4 | 1.5 | 17.5 | 2.2 | 0 |
Gentamicin | 4 | 1.6 | 0 | 1.6 | 2.2 | 0 |
Nalidixic acid | 23 | 7.3 | 4.5 | 1.6 | 4.4 | 2.6 |
Ciprofloxacin | 0 | 0 | 0 | 0 | 0 | 0 |
Sulfonamides | 29 | 10.5 | 4.5 | 19.8 | 8.8 | 0 |
Trimethoprim | 10 | 4 | 3 | 1.6 | 4.4 | 0 |
Chloramphenicol | 25 | 9.7 | 1.5 | 15.9 | 8.8 | 0 |
Tetracycline | 27 | 11.3 | 3 | 19 | 9.9 | 3.8 |
*n, no. of isolates studied; N, no. of isolates received at the French National Reference Centre for Salmonella (1 per patient).
1Current affiliation: Institut Pasteur, St. Petersburg, Russia.
2Current affiliation: Institut Pasteur, Casablanca, Morocco.
Page created: July 09, 2010
Page updated: July 09, 2010
Page reviewed: July 09, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.